Effects of weekly bevacizumab and paclitaxel/carboplatin with or without sorafenib on heavily pretreated patients with recurrent or persistent cervical cancer.

被引：3
|
作者：
Kikuchi, Y.
Takano, M.
Goto, T.
Kouta, H.
Kikuchi, R.
Kudoh, K.
Kita, T.
Furuya, K.
Umayahara, K.
Takizawa, K.
机构：
[1] Ohki Mem Canc Ctr Women, Tokorozawa, Saitama, Japan
[2] Natl Def Med Coll, Tokorozawa, Saitama 359, Japan
[3] Natl Hosp Org, Nishi Saitama Chuo Hosp, Tokorozawa, Saitama, Japan
[4] Nara Prefectural Nara Hosp, Nara, Japan
[5] Canc Inst Hosp, Ariake, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.5085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5085
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effect of weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with heavily pretreated ovarian cancer
    Ikeda, Yuji
    Kikuchi, Yoshihiro
    Takano, Masashi
    Goto, Tomoko
    Kouta, Hiroko
    Sasaki, Naoki
    Kudoh, Kazuya
    Oda, Katsutoshi
    Nagasaka, Tsuneki
    Kita, Tsunekazu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer
    Torfs, Sofie
    Cadron, Isabelle
    Amant, Frederic
    Leunen, Karin
    Berteloot, Patrick
    Vergote, Ignace
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (09) : 1332 - 1340
  • [23] Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer
    McNamara, Blair
    Chang, Yifan
    Mutlu, Levent
    Harold, Justin
    Santin, Alessandro D.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (03) : 227 - 233
  • [24] A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis
    Ishikawa, Mitsuya
    Shibata, Taro
    Iwata, Takashi
    Nishio, Shin
    Takada, Toshio
    Suzuki, Shiro
    Horie, Koji
    Kudaka, Wataru
    Kagabu, Masahiro
    Tanikawa, Michihiro
    Kitagawa, Ryo
    Takekuma, Munetaka
    Kobayashi, Hiroaki
    Yaegashi, Nobuo
    GYNECOLOGIC ONCOLOGY, 2021, 162 (02) : 292 - 298
  • [25] Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311)
    Ishikawa, Mitsuya
    Shibata, Taro
    Kataoka, Tomoko
    Takekuma, Munetaka
    Kobayashi, Hiroaki
    Yaegashi, Nobuo
    Satoh, Toyomi
    Gynecol Canc Study Grp
    Japan Clin Oncol Grp
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (05) : 692 - 700
  • [26] Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer
    Angeles Alvarez Secord
    Laura J. Havrilesky
    Michael E. Carney
    John T. Soper
    Daniel L. Clarke-Pearson
    Gustavo C. Rodriguez
    Andrew Berchuck
    International Journal of Clinical Oncology, 2007, 12 : 31 - 36
  • [27] Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer
    Secord, Angeles Alvarez
    Havrilesky, Laura J.
    Carney, Michael E.
    Soper, John T.
    Clarke-Pearson, Daniel L.
    Rodriguez, Gustavo C.
    Berchuck, Andrew
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (01) : 31 - 36
  • [28] CECILIA: AN OPEN-LABEL GLOBAL SAFETY STUDY EVALUATING BEVACIZUMAB, CARBOPLATIN AND PACLITAXEL THERAPY IN PATIENTS WITH METASTATIC, RECURRENT OR PERSISTENT CERVICAL CANCER (CC)
    Redondo, A.
    Colombo, N.
    McCormack, M.
    Nogueira-Rodrigues, A.
    Martin, N.
    Bastiere-Truchot, L.
    Gonzalez-Martin, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 201 - 201
  • [29] Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma
    Piura, B
    Meirovitz, M
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2005, 26 (04) : 386 - 390
  • [30] Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
    Ilhan, Yusuf
    Tatli, Ali Murat
    Teker, Fatih
    Onder, Arif Hakan
    Kose, Fatih
    Geredeli, Caglayan
    Karaagac, Mustafa
    Kaplan, Muhammet Ali
    Inanc, Mevlude
    Aydin, Sabin Goktas
    Kargi, Aysegul
    Arak, Haci
    Ozturk, Banu
    Besen, Ali Ayberk
    Selvi, Oguzhan
    Korkmaz, Mustafa
    Oruc, Zeynep
    Bozkurt, Oktay
    Bilici, Ahmet
    Bayram, Selami
    Dae, Shute Ailia
    Ozdogan, Mustafa
    Coskun, Hasan Senol
    Goksu, Sema Sezgin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (04) : 502 - 507
12345